Related Experiment Video
Updated: Dec 23, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
[Neoadjuvant and adjuvant treatment of pancreatic cancer]
C Springfeld1, T Hackert2, D Jäger3
1Abteilung Medizinische Onkologie, Nationales Zentrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland. christoph.springfeld@med.uni-heidelberg.de.
Background:
Resection is the only curative treatment option for pancreatic cancer patients. Adjuvant chemotherapy can improve disease-free survival and overall survival after resection. Furthermore, neoadjuvant treatment protocols are currently being investigated in a large number of studies.
Objective:
Summary of the current evidence for adjuvant and neoadjuvant treatment.
Material And Methods:
Review of the current scientific literature and guidelines.
Results And Conclusion:
After resection for pancreatic cancer patients should receive intensive chemotherapy with mFOLFIRINOX, gemcitabine plus capecitabine or gemcitabine/5-fluorouracil (5-FU) monotherapy. Neoadjuvant treatment concepts are promising but have to be further evaluated in prospective studies.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Acute Pancreatitis II: Clinical Manifestations and Management